Pan-genotypic direct-acting antivirals for patients with hepatitis C virus infection and chronic kidney disease stage 4 or 5

Hepatitis C virus (HCV) infection is a major health problem with significant clinical and economic burdens in patients with chronic kidney disease (CKD) stage 4 or 5. Current guidelines recommend pan-genotypic direct-acting antivirals (DAAs) to be the first-line treatment of choice for HCV. This rev...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Chen-Hua, Kao, Jia-Horng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer India 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309604/
https://www.ncbi.nlm.nih.gov/pubmed/35876967
http://dx.doi.org/10.1007/s12072-022-10390-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309604/
https://www.ncbi.nlm.nih.gov/pubmed/35876967
http://dx.doi.org/10.1007/s12072-022-10390-z

Ejemplares similares